ARID1A expression in gastric adenocarcinoma: Clinicopathological significance and correlation with DNA mismatch repair status

Table 2 Clinicopathologic features of the 489 patients with gastric cancers according to mismatch repair status n (%)

	Total(n = 489)	MMR		P value
		Deficient (n = 38)	Intact(n = 451)
Age (yr)				< 0.0011
mean ± SD	61.0 ± 11.8	68.6 ± 9.2	60.4 ± 11.7
Gender				0.0042
Male	327 (66.9)	17 (44.7)	310 (68.7)
Female	162 (33.1)	21 (55.3)	141 (31.3)
Serum CEA (ng/mL)				0.9101
mean ± SD	36.3 ± 315.7	4.4 ± 6.0	39.0 ± 328.7
Tumor size (mm)				0.8311
mean ± SD	80.3 ± 45.1	79.0 ± 38.9	80.4 ± 45.6
Tumor location				0.0212
Fundus and Corpus	356 (72.8)	21 (55.3)	335 (74.3)
Antrum	133 (27.2)	17 (44.7)	116 (25.7)
Histology				0.0232
Differentiated type	193 (39.5)	22 (57.9)	171 (37.9)
Undifferentiated type	296 (60.5)	16 (42.1)	280 (62.1)
Lymphatic invasion				1.0002
Absent	137 (28.0)	10 (26.3)	127 (28.2)
Present	352 (72.0)	28 (73.7)	324 (71.8)
Venous invasion				0.6092
Absent	281 (57.5)	20 (52.6)	261 (57.9)
Present	208 (42.5)	18 (47.4)	190 (42.1)
Primary tumor				0.6122
T2, 3	241 (49.3)	22 (57.9)	219 (48.6)
T4	248 (50.7)	16 (42.1)	232 (51.4)
Lymph node involvement				0.4382
N0	118 (24.1)	11 (28.9)	107 (23.7)
N1, 2, 3	371 (75.9)	27 (71.1)	344 (76.3)
Distant metastasis				0.2022
M0	336 (68.7)	30 (78.9)	306 (67.8)
M1	153 (31.3)	8 (21.1)	145 (32.2)
Stage				0.8602
Stage I, II	172 (35.2)	14 (36.8)	158 (35.0)
Stage III, IV	317 (64.8)	24 (63.2)	293 (65.0)
Residual disease				0.1612
Negative	375 (76.7)	33 (86.8)	342 (75.8)
Positive	114 (23.3)	5 (13.2)	109 (24.2)

¹Mann-Whitney U test;

²Fisher’s exact test. MMR: Mismatch repair; CEA: Carcinoembryonic antigen.